Current treatments for chronic hepatitis B virus infections

Abstract : Over 240 million people worldwide are chronically infected with hepatitis B virus (HBV) and although a prophylactic vaccine and effective antiviral therapies are available, no cure exists. Curative regimens are urgently needed because up to one million deaths per year are caused by HBV-related liver cancer and end-stage liver disease. HBV is an hepatotropic virus which belongs to the Hepadnaviridae family and replicates its DNA genome via a reverse transcriptase mechanism. Effective therapies have been developed for chronic hepatitis B (CHB) infection in the last two decades. They rely on the use of interferon alpha and its pegylated formulation, and on nucleos(t)ide analogs that inhibit viral polymerase activity. Their results are discussed in this review as well as future perspectives
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796195
Contributor : Lauriane Pillet <>
Submitted on : Saturday, May 19, 2018 - 11:34:27 AM
Last modification on : Friday, May 25, 2018 - 7:06:45 PM

Identifiers

Collections

Citation

Fabien Zoulim, Fanny Lebossé, Massimo Levrero. Current treatments for chronic hepatitis B virus infections. Current Opinion in Virology, Elsevier, 2016, 18, pp.109-116. ⟨http://linkinghub.elsevier.com/retrieve/pii/S1879625716300669⟩. ⟨10.1016/j.coviro.2016.06.004⟩. ⟨hal-01796195⟩

Share

Metrics

Record views

45